Press release
Schizophrenia FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Schizophrenia Pipeline Report
* In January 2025:- LB Pharmaceuticals Inc.:- This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days.
* In January 2025:- Click Therapeutics Inc.: The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an adjunct treatment to SOC in participants 18 years of age or older diagnosed with experiential negative symptoms of schizophrenia.
* In January 2025:- Cerevel Therapeutics Inc.:- The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
* In January 2025:- Spinogenix:- This Phase 2 study will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia. This is a randomized, placebo-controlled study of SPG302 administered once daily for six weeks. This study will entail five visits to the study site for screening, study procedures, and receipt of investigational medication for use at home.
* DelveInsight's Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
* The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Emerging Drugs Profile
* LYN-005: Lyndra Therapeutics
LYN-005 is an innovative, long-acting oral formulation of risperidone being developed by Lyndra Therapeutics for the treatment of schizophrenia and schizoaffective disorders. This medication is designed to be taken once a week, significantly reducing the pill burden associated with daily dosing regimens. The development of LYN-005 aims to enhance medication adherence and improve therapeutic outcomes for patients who struggle with consistent daily medication intake.
* Emraclidine: AbbVie
Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.
* HS-10380: Jiangsu Hansoh Pharmaceutical
HS10380 is an investigational antipsychotic drug developed by Jiangsu Hansoh Pharmaceutical and Shanghai Hansoh Biomedical. This novel compound is being researched for its potential to treat psychiatric disorders, primarily schizophrenia and related conditions. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Schizophrenia.
* KYN-5356: Kynexis
KYN-5356 is a clinical-stage small molecule developed by Kynexis Pharmaceuticals, targeting the enzyme Kynurenine Aminotransferase II (KAT-II), a key component in the kynurenine pathway. This pathway is involved in the production of neuroactive metabolites, which play a role in neurological disorders such as schizophrenia. By inhibiting KAT-II, KYN-5356 reduces the production of kynurenic acid, a metabolite that blocks NMDA receptors and has been linked to cognitive impairment. KYN-5356 is being developed specifically for treating cognitive impairment associated with schizophrenia (CIAS), aiming to restore cognitive function by modulating glutamatergic neurotransmission through this targeted inhibition.
Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Companies
Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Schizophrenia Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Schizophrenia Pipeline Report
* Coverage- Global
* Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others
* Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Schizophrenia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Schizophrenia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LYN-005: Lyndra Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Emraclidine: Abbvie
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* KYN-5356: Kynexis
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Schizophrenia Key Companies
* Schizophrenia Key Products
* Schizophrenia- Unmet Needs
* Schizophrenia- Market Drivers and Barriers
* Schizophrenia- Future Perspectives and Conclusion
* Schizophrenia Analyst Views
* Schizophrenia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-fda-approvals-clinical-trials-emerging-drugs-pipeline-insights-and-companies-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight here
News-ID: 3849952 • Views: …
More Releases from ABNewswire
The Silver Clover & Co. Transforms Black Friday into Meaningful Investment in Re …
Jewelry retailer reframes Black Friday shopping as opportunity for intentional gift-giving that creates lasting memories rather than impulse purchases
While Black Friday traditionally emphasizes discounts and volume purchasing, The Silver Clover & Co. proposes a different approach: using the shopping event as catalyst for intentional investment in relationships through meaningful jewelry gifts that combine lasting beauty, personal storytelling, and luxury presentation. The emerging jewelry retailer's innovative message card system and presentation…
Stuart Packwood: The Visionary Leader Driving Excellence and Innovation at B-Spo …
B-Spoke Systems Ltd proudly highlights the inspiring leadership and unwavering professional excellence of Stuart Packwood, a respected business owner and driving force behind the company's long-standing success in the UK's EPOS and technology solutions market.
Leicester, UK - 18 November, 2025 - B-Spoke Systems Ltd proudly highlights the inspiring leadership and unwavering professional excellence of Stuart Packwood, a respected business owner and driving force behind the company's long-standing success in the…
LPGA Hall of Famer Annika Sorenstam's Foundation Chooses Wedge Game for Winter G …
The ANNIKA Foundation trusts Wedge Game's innovative training system for youth golf development, highlighting the product's professional credibility. With holiday season approaching, golf retailers report surge in demand for the space-saving practice solution.
Wedge Game Group, Inc. strengthens its position in the golf training market as the ANNIKA Foundation continues its exclusive use of the Wedge Game system across all golf clinics, setting a new standard for indoor golf practice equipment…
Frederick Fisher Educates Policyholders on the Right Time to Report an Insurance …
El Segundo, CA - What do USC, Harvard University, and Wayfarer have in common? They all had knowledge that something was awry, started internal investigations, had discussions internally, but never notified their insurance companies that there was a problem that could later give rise to a claim or lawsuit.
When renewal applications were filled out, they stated that they were unaware of any act or action that could later give rise…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Critical …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Schizophrenia Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The financial scope of the schizophrenia market has shown consistent expansion lately, projected to see an increase from a valuation of $5.82 billion in 2024 to $6.06 billion by 2025, reflecting a compound annual growth rate…
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
